This is the authors' abstract. We don't add key points for this paper.
The most prevalent risk factor of Alzheimer's disease (AD) is carrying the ε4 allele which is coding for apolipoprotein E4 (apoE4). ApoE4 carriers have dysfunctional apoE as characterized by perturbed cholesterol and phospholipid uptake from glial cells with downstream effects related to cell viability, neuroplasticity and cognition. In addition AD patients show, elevated concentrations of amyloidbeta42 (Aβ42), decreased levels of the presynaptic transporter VGluT1 and elevated concentrations of phosphorylated tau (P-tau). These human apoE4 AD features were replicated in human apoE4 target replacement mice (in contrast to human apoE3 replacement mice) thus providing a pharmacological model for assessing therapeutic modalities in apoE4 AD. In a lead selection two ABCA1 agonist with favorable brain penetration were compared for their efficacy assessing AD phenotype characteristics in the hippocampus showing superior effects by CogpepB. CogpepB dose-response was assessed by administering 20 and 60mg/kg/48 hour for 6 weeks assessing Novel Object Recognition, NOR). A highly statistically significant improvement in NOR compared to placebo was found by the lower dose with no additional benefit by the higher dose. In a 3study 20mg/kg/48h CogpepB was administered for 6 weeks to apoE4 and apoE3 mice and compared to placebo assessing Morris water maze test derived cognition which showed highly significant improvement in the apoE4 active group to that of the apoE3 mice. Interestingly, CogpepB treatment had no effect on apoE3 mice suggesting that the treatment effect is limited to apoE4 mice, potentially by correction of apoE4’s conformational restrictions with regard to ABCA1 interaction and lipid transfer from cells to extra-cellular apoE4. This mechanism of action notion was supported by direct demonstration of increased apoE4 lipidation by CogpepB. Taken together the findings suggest that an ABCA1 agonist, CogpepB, designed from the lipid binding segment of apoE is able to correct the apoE4 lipidation insufficiency thereby normalizing apoE4 phenotype and cognition. CogpepB therefore represents a novel therapeutic approach to apoE4 AD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Boehm‐Cagan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: